 |
NEWS RELEASE
FOR IMMEDIATE RELEASE
DICKEN S. C. KO, MD, FRCSC, FACS JOINS SINOBIOMED, INC. ADVISORY BOARD
Highly regarded consultant strengthens an international multidisciplinary scientific advisory team
Shanghai, China – April 30, 2007 – Sinobiomed Inc. ("Sinobiomed", "the Company") (OTCBB: SOBM) is pleased to announce that Dr. Dicken Shiu-Chung Ko, B.SC, M.D., F.R.C.S.C., F.A.C.S, has joined Sinobiomed's Advisory Board. Highly regarded globally for his involvement in developing new medical therapies and techniques, Dr. Ko has over the past decade served as a consultant to leading biomedical device and pharmaceutical companies. He is currently the Surgical Director of the Renal Transplant Program at Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School in Boston.
Dr. Ko's proven expertise will strengthen Sinobiomed's product development pipeline and complements the work of its international multidisciplinary team, which includes Dr. Tom Chen of Rockville, Maryland, USA, and Dr. Weiqing Pan, Dr. Jianzhi Xiang, and Prof. Yu-Yang Li, all based in Shanghai, China. Dr. Ko has outstanding experience in clinical multi-organ transplantation, basic immunology, viral hepatitis treatment, surgical product developments, and urological minimally invasive surgery. This combination is not only unique but also diversified, enabling Dr. Ko to respond to many of the Company's multiple advisory requirements.
"Dr. Ko's knowledge and skills will significantly benefit the Company's efforts to develop life-saving biopharmaceutical products," said President and CEO Banyun Yang. "We are very proud and grateful that he has chosen to join the Sinobiomed Advisory Board."
Dr. Ko received his medical training in Canada, first at Queen's University in Ontario, followed by urology specialization at University of British Columbia. He has fellowships in clinical transplantation and research in transplantation biology and is active in 8 national and 3 international medical/surgical societies, holding leadership positions in national committees in many of them. Dr. Ko is also a frequent speaker at international forums and national symposiums.
Sinobiomed's team of international advisors will work closely with Dr. Tom Chen, the Company's Chief Technical Consultant, on existing products and emerging technologies. Of particular note, Dr. Chen, Vice President of Process Development at Prometic BioTherapeutics in Rockville, is working on Sinobiomed's US and Chinese patented malaria vaccine in collaboration with the PATH Malaria Vaccine Initiative (MVI).
Dr. Pan is the inventor of the US patented malaria vaccine that Sinobiomed has exclusive rights to develop. Mr. Xiang, a specialist in biopharmaceutical drug evaluation, serves on the World Health Organization (WHO) Expert Committee on Biological Standardization, and Professor Li of Fudan University is a leader in foreign gene expression in yeast, a key element in the production process of Sinobiomed's malaria vaccine.
ABOUT SINOBIOMED INC.
SionBiomed's Shanghai Wanxing Bio-pharmaceuticals is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Shanghai, Wanxing currently has 10 products approved or in development: two on the market, one recently received approval, four in clinical trials and three in research and development. Shanghai Wanxing's products respond to a wide range of diseases and conditions, including malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration. Shanghai Wanxing also has proven expertise in recombinant protein manufacturing technology and a patented lowcost, high-yield production process to enhance bioactivity and guarantee the highest levels or purity. (www.sinobiomed.com)
Contact:
Sinobiomed Investor Relations | Toll Free: 1-866-588-0829 | Email: info@sinobiomed.com |
